Jason Hsu insider trades
Open-market stock purchases and sales by Jason Hsu, Director at Immix Biopharma, Inc, from SEC Form 4 filings since Dec 20, 2021.
Track record: 100% of 14 scored buys are up 5% or more since purchase, averaging +198%.
Companies traded
- IMMX Immix Biopharma, Inc: 14 buys, last May 22, 2026